Table 2.
Sociodemographic and clinical characteristics (n = 54).
| Variable | n (%) or Mdn (range) |
|---|---|
| Age (years) | 53 (19–91)a |
| Months post-diagnosis | 4 (1–81) |
| Sex | |
| Male | 24 (44) |
| Female | 30 (56) |
| Years of education | 12 (6–16) |
| Histological diagnosis | |
| Astrocytoma Grade 1–2 | 6 (11.1) |
| Astrocytoma Grade 3 | 4 (7.4) |
| Glioblastoma grade 4 | 16 (29.6) |
| Oligodendroglioma/oligoastrocytoma Grade 2–3 | 4 (7.4) |
| Meningioma | 15 (27.8) |
| Otherb | 9 (16.7) |
| Tumor grade/type | |
| High-grade glioma | 21 (38.9) |
| Low-grade glioma | 12 (22.2) |
| Benign PBT | 21 (38.9) |
| Tumor site | |
| Frontal/temporal | 29 (53.7) |
| Other | 25 (46.3) |
| Tumor lateralization | |
| Left-side | 24 (44.4) |
| Right-side | 22 (40.8) |
| Both | 8 (14.8) |
| Treatment stagec | |
| Post-surgery | 3 (5.6) |
| Active treatment (RT, chemotherapy) | 15 (27.8) |
| Post-treatment | 35 (64.8) |
| Palliative | 1 (1.9) |
| Neurosurgical intervention | |
| Biopsy | 12 (22.2) |
| Resection (sub or gross total) | 42 (77.8) |
| Radiation therapy | |
| Yes | 32 (59.3) |
| No | 22 (40.7) |
| Chemotherapy | |
| Temozolomide | 16 (29.6) |
| Other | 1 (1.9) |
| None | 37 (68.5) |
| Radiation (RT) dose | |
| 5040–6000 cGy | 30 (55.6) |
| <5040 cGy | 2 (3.5) |
| None | 22 (40.7) |
| Epileptic seizures | |
| Yes | 25 (46.3) |
| No | 29 (53.7) |
| Corticosteroids (current use) | |
| Yes | 10 (18.5) |
| No | 36 (66.7) |
| Unknown | 8 (14.8) |
| Karnofsky performance status | 80 (50–100) |
| 100–90 | 19 (35.2) |
| 80 | 23 (42.6) |
| 70–50 | 12 (22.2) |
aFor analysis of age and time post-diagnosis variables, group divided by median split ≥53 versus <53 years, and ≥4 versus <4 months, respectively.
bOther: craniopharyngioma n = 2, epidermoid tumor n = 1, ependymoma Grade 2 n = 2, medulloblastoma n = 1, pituitary adenoma n = 2, schwannoma n = 1.
cPost-treatment = disease monitoring phase with no active tumor treatment regimen, Palliative = no further active treatment indicated other than supportive care.